An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
Martin Gore(Imperial College London), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Allan Hackshaw(Cancer Research UK), Timothy Perren(University of Leeds), Sean Kehoe(University College Birmingham), Helen Christensen(Cancer Research UK), Raji Ganesan(Birmingham Women’s and Children’s NHS Foundation Trust), Gordon Rustin(Mount Vernon Cancer Centre), Richard J. Zaino(Pennsylvania State University), Nicholas Reed, Melanie Mackean(Edinburgh Cancer Research), Jonathan A. Ledermann(London Cancer), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), G. Dark(Freeman Hospital), Richard T. Penson(Massachusetts General Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Jeffrey Summers(Maidstone and Tunbridge Wells NHS Trust), Amanda Feeney(Cancer Research UK), Nafisa Wilkinson(University College London Hospitals NHS Foundation Trust), W. Glenn McCluggage(Belfast Health and Social Care Trust), William E. Brady(Pfizer (United States)), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust)
Cited by 104
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k